Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus and alcohol. The paradigm for treating HCV has radically changed over the last 20 years. The tolerability and duration of treating HCV patients was altered fundamentally by the emergence of modern and more efficacious treatment regimens and plans. Nevertheless, the risk of developing serious adverse reactions, including those due to drug–drug interactions, remains high. Currently, eight drugs are approved for treating HCV and avoid the use of interferons. The present article reviews these drugs with respect to their efficacy and safety for use in patients with various HCV genotypes. © 2018, Springer Science+Business Media, LLC, part of Spring...
Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and soc...
Journal Article; Review;About 130-170 million people, is estimated to be infected with the hepatitis...
Present study reports an update on the molecular interaction of antiviral drugs with viral and host ...
Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus ...
Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can be life-th...
Introduction: About 150 million people worldwide are estimated to be chronically infected with the h...
Copyright © 2013 J. González-Moreno and A. Payeras-Cifre.This is an open access article distributed...
It is estimated that currently, in the world, approximately 3% of the population has chronic hepatit...
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, p...
Abstract Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can b...
Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic ...
C1 - Journal Articles RefereedNewly licensed direct acting antivirals for hepatitis C virus HCV are ...
Copyright © 2013 Hee Bok Chae et al. This is an open access article distributed under the Creative C...
Introduction: Therapeutic options for patients with HCV-related liver disease have increased over th...
One of the most exciting developments in antiviral research has been the discovery of the direct-act...
Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and soc...
Journal Article; Review;About 130-170 million people, is estimated to be infected with the hepatitis...
Present study reports an update on the molecular interaction of antiviral drugs with viral and host ...
Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus ...
Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can be life-th...
Introduction: About 150 million people worldwide are estimated to be chronically infected with the h...
Copyright © 2013 J. González-Moreno and A. Payeras-Cifre.This is an open access article distributed...
It is estimated that currently, in the world, approximately 3% of the population has chronic hepatit...
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, p...
Abstract Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can b...
Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic ...
C1 - Journal Articles RefereedNewly licensed direct acting antivirals for hepatitis C virus HCV are ...
Copyright © 2013 Hee Bok Chae et al. This is an open access article distributed under the Creative C...
Introduction: Therapeutic options for patients with HCV-related liver disease have increased over th...
One of the most exciting developments in antiviral research has been the discovery of the direct-act...
Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and soc...
Journal Article; Review;About 130-170 million people, is estimated to be infected with the hepatitis...
Present study reports an update on the molecular interaction of antiviral drugs with viral and host ...